A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC
Clinical trial NCT07416695 · RECRUITING
Trial details
- NCT number
- NCT07416695
- Sponsor
- Shanghai Henlius Biotech
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-17
- Primary completion
- 2028-05-30
- Enrollment
- 138
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.